Israeli oral drug delivery developer Oramed has begun recruiting patients for a clinical trial of its oral insulin pill for patients with Type 1 diabetes mellitus. The pill, ORMD-0801, is set to undergo a Phase IIa trial for Type 2 diabetes, as well, getting closer to becoming the first orally digestible insulin capsule on the market. Meanwhile, other companies such as Novo Nordisk ($NVO), Bristol-Myers Squibb ($BMY) and India's Biocon are champing at the bit to launch insulin pills of their own. Release